ArticleFrontiers in public health2026
Direct hospitalization costs of children with
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Immunopathogenesis, molecular phenotyping, and host-directed interventions for severe pediatricFrontiers in cellular and infection microbiology · 2026Review
- A nursing perspective on bronchoscopic intervention strategies for children with macrolide-unresponsiveFrontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: This study conducted a retrospective analysis of pediatric patients diagnosed with MPP and hospitalized at Shanghai Children's Medical Center over a 13-year period, from January 2013 to June 2025. The duration of hospital stay, total hospitalization costs, and drug costs per hospitalization were analyzed by year, corticosteroid administration, and presence of macrolide-resistant genes. Results: A total of 4,684 hospitalized children with MPP were included. The median age of the cohort was 6.50 years (quartile: 4.20-8.30 years), and the median duration of hospital stay was 5.00 days (quartile: 4.00-7.00 days). The median cost per hospitalization was $1,250.52 (quartile: $1,016.06-$1,612.27), while the median drug cost per hospitalization was $124.02 (quartile: $75.00-$199.31). Significant differences were observed in the duration of hospital stay, total costs, and drug costs per hospitalization between the age groups < 3, 3-6, 6-10, and ≥10 years. Additionally, significant differences were found between patients who received corticosteroids and those who did not, in terms of hospital stay duration, total costs, and drug costs per hospitalization. Conclusions: The medical burden associated with MPP in children under 3 years of age warrants attention and should be a focus of medical reimbursement policy considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.